

## Title Giant Cell Arteritis

---

Reference Number: RDF2002-23

Date of Response: 13/11/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1<sup>st</sup> April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Q1. Does your trust or health board treat giant cell arteritis (GCA)? If not, please provide the name of the hospital or trust that you refer GCA patients to. Answer - Yes

Q2. In the past 3 months, how many patients with a primary diagnosis of GCA (ICD10 codes M31.5 or M31.6) were:

Admitted as an inpatient Answer - 9

Treated in A&E Answer - 10

Q3. How many patients were treated by the rheumatology department in the past 3 months with the following:

Tocilizumab – for any disease - Answer 66

Tocilizumab for rheumatoid arthritis (RA) only Answer 43

Tocilizumab for giant cell arteritis (GCA) only. Answer 13

Q4. How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab? Answer - 0

Q5. How many patients were treated in A&E in the past 3 months for giant cell arteritis (GCA) with Tocilizumab? Answer - 0